Cargando…

The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment

Bladder cancer (BC) is the most frequently occurring cancer of the urinary system, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75–85% of all the bladder cancers. Patients with NMIBC have a good survival rate but are at high risk for tumor recurrence and disease progression. Intrav...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chong, Wang, Shuai, Lai, Wing-Fu, Zhang, Dahong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861699/
https://www.ncbi.nlm.nih.gov/pubmed/36678840
http://dx.doi.org/10.3390/pharmaceutics15010211
_version_ 1784874906964459520
author Yu, Chong
Wang, Shuai
Lai, Wing-Fu
Zhang, Dahong
author_facet Yu, Chong
Wang, Shuai
Lai, Wing-Fu
Zhang, Dahong
author_sort Yu, Chong
collection PubMed
description Bladder cancer (BC) is the most frequently occurring cancer of the urinary system, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75–85% of all the bladder cancers. Patients with NMIBC have a good survival rate but are at high risk for tumor recurrence and disease progression. Intravesical instillation of antitumor agents is the standard treatment for NMIBC following transurethral resection of bladder tumors. Chemotherapeutic drugs are broadly employed for bladder cancer treatment, but have limited efficacy due to chemo-resistance and systemic toxicity. Additionally, the periodic voiding of bladder and low permeability of the bladder urothelium impair the retention of drugs, resulting in a weak antitumoral response. Chitosan is a non-toxic and biocompatible polymer which enables better penetration of specific drugs to the deeper cell layers of the bladder as a consequence of temporarily abolishing the barrier function of urothelium, thus offering multifaceted biomedical applications in urinary bladder epithelial. Nowadays, the rapid development of nanoparticles significantly improves the tumor therapy with enhanced drug transport. This review presents an overview on the state of chitosan-based nanoparticles in the field of intravesical bladder cancer treatment.
format Online
Article
Text
id pubmed-9861699
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98616992023-01-22 The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment Yu, Chong Wang, Shuai Lai, Wing-Fu Zhang, Dahong Pharmaceutics Review Bladder cancer (BC) is the most frequently occurring cancer of the urinary system, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75–85% of all the bladder cancers. Patients with NMIBC have a good survival rate but are at high risk for tumor recurrence and disease progression. Intravesical instillation of antitumor agents is the standard treatment for NMIBC following transurethral resection of bladder tumors. Chemotherapeutic drugs are broadly employed for bladder cancer treatment, but have limited efficacy due to chemo-resistance and systemic toxicity. Additionally, the periodic voiding of bladder and low permeability of the bladder urothelium impair the retention of drugs, resulting in a weak antitumoral response. Chitosan is a non-toxic and biocompatible polymer which enables better penetration of specific drugs to the deeper cell layers of the bladder as a consequence of temporarily abolishing the barrier function of urothelium, thus offering multifaceted biomedical applications in urinary bladder epithelial. Nowadays, the rapid development of nanoparticles significantly improves the tumor therapy with enhanced drug transport. This review presents an overview on the state of chitosan-based nanoparticles in the field of intravesical bladder cancer treatment. MDPI 2023-01-07 /pmc/articles/PMC9861699/ /pubmed/36678840 http://dx.doi.org/10.3390/pharmaceutics15010211 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yu, Chong
Wang, Shuai
Lai, Wing-Fu
Zhang, Dahong
The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment
title The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment
title_full The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment
title_fullStr The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment
title_full_unstemmed The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment
title_short The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment
title_sort progress of chitosan-based nanoparticles for intravesical bladder cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861699/
https://www.ncbi.nlm.nih.gov/pubmed/36678840
http://dx.doi.org/10.3390/pharmaceutics15010211
work_keys_str_mv AT yuchong theprogressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment
AT wangshuai theprogressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment
AT laiwingfu theprogressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment
AT zhangdahong theprogressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment
AT yuchong progressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment
AT wangshuai progressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment
AT laiwingfu progressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment
AT zhangdahong progressofchitosanbasednanoparticlesforintravesicalbladdercancertreatment